VSTM - Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline
2025-08-08 14:49:44 ET
More on Verastem
- Verastem: The Market Is Ignoring The Progress
- Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
- Verastem Q2 2025 Earnings Preview
- Verastem Oncology gets FDA fast track status for cancer drug
- Seeking Alpha’s Quant Rating on Verastem